- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07950501
DOTA-1: Single-Fraction MR-guided Stereotactic Ablative Radiotherapy for Localized Prostate Cancer (DOTA-1)
DOminant-TArgeted Stereotactic Ablative Radiotherapy in Localized Prostate Cancer: Single-fraction Phase I/II Pilot Study (DOTA-1)
This single-center, single-arm phase I/II pilot study evaluates the safety and feasibility of single-fraction stereotactic body radiotherapy (SBRT) with a simultaneous integrated boost to the dominant intraprostatic lesion (DIL) in men with localized prostate cancer.
Ten participants with very low-, low-, or favorable intermediate-risk prostate adenocarcinoma and an MRI-visible DIL (PI-RADS 4-5) will be enrolled. After hydrogel rectal spacer insertion, patients receive MR-guided SBRT on an MR-Linac in one fraction: 20 Gy to the whole prostate, 26 Gy to the DIL, and 15 Gy to the seminal vesicles. The aim is to deliver a brachytherapy-like ablative dose without an invasive procedure.
The primary outcome is acute genitourinary and rectal toxicity (CTCAE v5.0) within 3 months after treatment. Secondary outcomes include late toxicity, patient-reported quality of life (IPSS, IIEF, FACT-P), biochemical failure-free survival (Phoenix definition), local recurrence-free, progression-free, distant metastasis-free and overall survival, correlation of MR-radiomics with clinical outcomes, and cost-effectiveness. Patients will be followed for 5 years.
Studieoversikt
Status
Forhold
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Ratchapas Romrattaphan, MD
- Telefonnummer: +6624197229
- E-post: ratchapas.rom@gmail.com
Studiesteder
-
-
Bangkok
-
Bangkok Noi, Bangkok, Thailand, 10700
- Rekruttering
- Siriraj Hospital
-
Ta kontakt med:
- Ratchapas Romrattaphan, MD
- Telefonnummer: +6624197229
- E-post: ratchapas.rom@gmail.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Men ≥ 18 years old
-
Newly diagnosed and histologically confirmed localized prostate adenocarcinoma
-
Very low-, low-, and favorable intermediate-risk via NCCN risk group classification, defined as;
- Gleason grade group 1 or 2
- Clinical stage T1-T2c
- Initial PSA < 20 ng/ml (Patient can have only one of cT2b-cT2c, Gleason grade group 2 and PSA 10-20 ng/ml)
-
Visible dominant-intraprostatic lesion (DIL) on multi-parametric MRI defined by PI-RADS classification
-
ECOG Performance Status 0-2 within 28 days prior to study entry
-
Patients must be able to provide study-specific informed consent prior to study entry.
Exclusion Criteria:
- Direct extraprostatic extension into the adjacent structures
- Extraprostatic metastases or malignant nodes
- Large prostate volume > 60 cm3 by imaging
- Use of Androgen deprivation therapy
- Baseline IPSS > 13
- MRI-contraindicated patient (eg., MRI-incompatible pacemaker, metal implant)
- Patient with hip prosthesis which causes artifact on MR images
- Patient with significant predisposing comorbidity (eg. inflammatory bowel disease)
- Prior radiotherapy to the region of the pelvis that would result in excessive doses to normal tissues due to overlap of radiation therapy fields
- Prior invasive malignancy (except non-melanomatous skin cancer) unless disease-free for a minimum of 2 years (Note that carcinoma in situ of the breast, oral cavity, or cervix are all permissible)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Single-fraction MR-guided SBRT
|
A single fraction of stereotactic body radiotherapy (SBRT) delivered on a 1.5T MR-Linac with daily MRI guidance, using IMRT with a simultaneous integrated boost. Prescribed doses: 26 Gy to the dominant intraprostatic lesion (DIL; PI-RADS 4-5 lesion on multiparametric MRI), 20 Gy to the whole prostate, and 15 Gy to the seminal vesicles. A hydrogel rectal spacer is inserted before CT/MR simulation. Before simulation and treatment, patients follow a bladder protocol (void, then drink 200-300 mL of water) and empty the rectum. No androgen deprivation therapy is given.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of Acute toxicity (Genitourinary and Gastrointestinal toxicity)
Tidsramme: Up to 3 months after SBRT
|
Incidence of acute treatment-related toxicity from the date of treatment by radiotherapy up to 3 months after completion of radiotherapy, assessed using CTCAE version 5.0 |
Up to 3 months after SBRT
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of Late toxicity (Genitourinary and Gastrointestinal toxicity)
Tidsramme: From 3 months to 5 years after SBRT
|
Incidence of late (chronic) treatment-related toxicity from 3 months after completion of radiotherapy up to 5 years after completion of radiotherapy, assessed using CTCAE version 5.0 |
From 3 months to 5 years after SBRT
|
|
International Prostate Symptom Score (I-PSS)
Tidsramme: Baseline and at each follow-up visit up to 5 years after SBRT
|
Patient-reported urinary symptoms assessed using the I-PSS. The total score ranges from 0 to 35; higher scores indicate worse urinary symptoms. |
Baseline and at each follow-up visit up to 5 years after SBRT
|
|
International Index of Erectile Function (IIEF-5) score
Tidsramme: Baseline and at each follow-up visit up to 5 years after SBRT
|
Patient-reported erectile function assessed using the IIEF-5 Score. The total score ranges from 5 to 25; higher scores indicate better erectile function. |
Baseline and at each follow-up visit up to 5 years after SBRT
|
|
Functional Assessment of Cancer Therapy - Prostate (FACT-P) score
Tidsramme: Baseline and at each follow-up visit up to 5 years after SBRT
|
Health-related quality of life assessed using the FACT-P. The total score ranges from 0 to 156; higher scores indicate better quality of life. |
Baseline and at each follow-up visit up to 5 years after SBRT
|
|
Freedom from biochemical failure
Tidsramme: 5 years after SBRT
|
Time from SBRT to biochemical failure, defined by the Phoenix criteria (PSA nadir + 2 ng/mL), estimated by the Kaplan-Meier method. |
5 years after SBRT
|
|
Local recurrence-free survival
Tidsramme: 5 years after SBRT
|
Time from SBRT to recurrence within the prostate, estimated by the Kaplan-Meier method. |
5 years after SBRT
|
|
Overall survival
Tidsramme: 5 years after SBRT
|
Time from SBRT to death from any cause, estimated by the Kaplan-Meier method. |
5 years after SBRT
|
|
Incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY)
Tidsramme: 5 years after SBRT
|
Cost and utility data will be used to evaluate cost-effectiveness by calculating the incremental cost-effectiveness ratio (ICER). Uncertainty analyses will be performed using one-way sensitivity analysis, probabilistic sensitivity analysis, and threshold analysis. |
5 years after SBRT
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- Si 703/2568 (IRB4)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Individual participant data will not be shared outside the study team. The informed consent and ethics approval do not cover data sharing.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .